- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
ESMO Ovarian | Conference
Olaparib Plus Bevacizumab Prolongs Survival in Advanced Ovarian Cancer
October 02, 2019
Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer.
Niraparib Shows “Impressive” Survival Improvements in Advanced Ovarian Cancer
October 02, 2019
Maintenance therapy with niraparib may improve survival in patients with ovarian cancer.
PARP Inhibitor Plus Chemo Means More PFS in Ovarian Cancer
October 02, 2019
The results of the first therapy to use a PARP inhibitor with chemotherapy for patients with ovarian cancer were presented at ESMO Congress 2019.
Trametinib ‘New Standard of Care’ Option for Low-Grade Ovarian Cancer
October 02, 2019
A new study looked at trametinib's effect on survival and response rates in ovarian cancer.